These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28825750)

  • 1. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with
    Baum RP; Singh A; Benešová M; Vermeulen C; Gnesin S; Köster U; Johnston K; Müller D; Senftleben S; Kulkarni HR; Türler A; Schibli R; Prior JO; van der Meulen NP; Müller C
    Dalton Trans; 2017 Oct; 46(42):14638-14646. PubMed ID: 28825750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced
    Singh A; van der Meulen NP; Müller C; Klette I; Kulkarni HR; Türler A; Schibli R; Baum RP
    Cancer Biother Radiopharm; 2017 May; 32(4):124-132. PubMed ID: 28514206
    [No Abstract]   [Full Text] [Related]  

  • 3. Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.
    Müller C; Fischer E; Behe M; Köster U; Dorrer H; Reber J; Haller S; Cohrs S; Blanc A; Grünberg J; Bunka M; Zhernosekov K; van der Meulen N; Johnston K; Türler A; Schibli R
    Nucl Med Biol; 2014 May; 41 Suppl():e58-65. PubMed ID: 24360901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Humans Application of
    Baum RP; Singh A; Kulkarni HR; Bernhardt P; Rydén T; Schuchardt C; Gracheva N; Grundler PV; Köster U; Müller D; Pröhl M; Zeevaart JR; Schibli R; van der Meulen NP; Müller C
    J Nucl Med; 2021 Oct; 62(10):1391-1397. PubMed ID: 33547209
    [No Abstract]   [Full Text] [Related]  

  • 6. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative.
    Müller C; Zhernosekov K; Köster U; Johnston K; Dorrer H; Hohn A; van der Walt NT; Türler A; Schibli R
    J Nucl Med; 2012 Dec; 53(12):1951-9. PubMed ID: 23139086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging.
    Müller C; Vermeulen C; Johnston K; Köster U; Schmid R; Türler A; van der Meulen NP
    EJNMMI Res; 2016 Dec; 6(1):35. PubMed ID: 27108447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical investigations and first-in-human application of
    Müller C; Singh A; Umbricht CA; Kulkarni HR; Johnston K; Benešová M; Senftleben S; Müller D; Vermeulen C; Schibli R; Köster U; van der Meulen NP; Baum RP
    EJNMMI Res; 2019 Jul; 9(1):68. PubMed ID: 31346796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging.
    Favaretto C; Talip Z; Borgna F; Grundler PV; Dellepiane G; Sommerhalder A; Zhang H; Schibli R; Braccini S; Müller C; van der Meulen NP
    EJNMMI Radiopharm Chem; 2021 Nov; 6(1):37. PubMed ID: 34778932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
    Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K
    Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross section measurement of terbium radioisotopes for an optimized
    Dellepiane G; Casolaro P; Favaretto C; Grundler PV; Mateu I; Scampoli P; Talip Z; van der Meulen NP; Braccini S
    Appl Radiat Isot; 2022 Jun; 184():110175. PubMed ID: 35344829
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Favaretto C; Grundler PV; Talip Z; Landolt S; Sepini L; Köster U; Müller C; Schibli R; Geistlich S; van der Meulen NP
    J Nucl Med; 2023 Jul; 64(7):1138-1144. PubMed ID: 37201956
    [No Abstract]   [Full Text] [Related]  

  • 17. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of terbium-152 by heavy ion reactions and proton induced spallation.
    Allen BJ; Goozee G; Sarkar S; Beyer G; Morel C; Byrne AP
    Appl Radiat Isot; 2001 Jan; 54(1):53-8. PubMed ID: 11144253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
    Sänger PW; Freesmeyer M
    Clin Nucl Med; 2016 Jun; 41(6):447-53. PubMed ID: 26859210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
    Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.